What is Oasis Diagnostics?
Oasis Diagnostics Corporation operates at the intersection of molecular biology and point-of-care testing. The company specializes in the engineering of non-invasive saliva collection devices designed to standardize the extraction of RNA, DNA, and critical biomarkers. By streamlining the sample collection process, Oasis Diagnostics addresses significant inefficiencies in the in vitro diagnostics marketplace. Their patented technology suite is engineered to support high-throughput research environments while simultaneously providing robust solutions for clinical applications, thereby enhancing the precision of modern medical diagnostics and public health monitoring.
How much funding has Oasis Diagnostics raised?
Oasis Diagnostics has raised a total of $733K across 1 funding round:
Grant
$733K
Grant (2013): $733K with participation from National Institutes of Health
Key Investors in Oasis Diagnostics
National Institutes of Health
The National Institutes of Health is the primary agency of the United States government responsible for biomedical and health-related research, providing critical grant support for innovative medical technologies.
What's next for Oasis Diagnostics?
With the support of its recent capital allocation, Oasis Diagnostics is poised to accelerate the commercialization of its diagnostic pipeline. The strategic focus will likely shift toward expanding the reach of its point-of-care testing devices into broader clinical settings, where the demand for rapid, non-invasive biomarker analysis is increasing. As the company scales, it will continue to leverage its intellectual property to disrupt traditional diagnostic workflows, aiming to establish its saliva-based collection kits as the industry standard for both research and diagnostic utility. Future growth will be defined by the integration of these tools into routine clinical practice, further cementing the company's role as a key innovator in the global health technology landscape.
See full Oasis Diagnostics company page
